Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (5)
  • Autophagy
    (3)
  • HER
    (1)
  • PROTACs
    (1)
  • Others
    (2)
Filter
Search Result
Results for "

h3255

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    7
    TargetMol | Inhibitors_Agonists
  • PROTAC Products
    3
    TargetMol | PROTAC
Afatinib
BIBW 2992, Afatinib free base
T21312850140-72-6
Afatinib (BIBW 2992) is an irreversible inhibitor of the EGFR family (EGFR-wt, EGFR-L858R, EGFR-L858R T790M, and HER2) with IC50s of 0.5 nM, 0.4 nM, 10 nM, and 14 nM, respectively.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
ms 154
T411552550393-21-8In house
MS 154 is a potent and selective cereblon-recruiting Degrader (PROTAC®) of mutant epidermal growth factor receptor (EGFR), comprising a cereblon-binding moiety joined by a linker to gefitinib(Iressa). MS 154 decreases EGFR protein levels, inhibits downstream signaling in and inhibits proliferation of mutant EGFR-bearing lung cancer cells (DC50values are 11 and 25 nM in HCC-827 and H3255 cells, respectively; Dmax> 95% at 50 nM), but not in WT-EGFR-bearing ovarian and lung cancer cells lines. Bioavailable in mice following ip administration.
  • Inquiry Price
8-10 weeks
Size
QTY
Erlotinib
R1415, OSI-744, NSC 718781, CP358774
T0373183321-74-6
Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
Afatinib Dimaleate
BIBW2992, BIBW 2992MA2, Afatinib (BIBW2992) Dimaleate, Afatinib
T1773850140-73-7
Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
MS 39
T411562675490-92-1In house
MS 39 is a highly effective, highly affinity and selective depressant of mutant epidermal growth factor receptor (EGFR) with high efficiency, high affinity and selectivity. MS 39, conjured by gefitinib to VHL ligand via a linker, effectively induced the degradation of mutant EGFR (DC50 values in HCC827(exon 19 del) and H3255 (L858R mutation) lung cancer cell lines were 5 nM and 3.3 nM, respectively). However, there was no significant effect in wild-type EGFR cell lines with concentrations up to 10 μM. MS 39 inhibited the proliferation of H3255 lung cancer cells in vitro and was bioavailable in mice after administration.
  • Inquiry Price
6-8 weeks
Size
QTY
Gefitinib-based PROTAC 3
T54372230821-27-7
Gefitinib-based PROTAC 3, which connects an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827 (exon 19 del) and H3255 (L858R mutation) cells, respectively[1].
  • Inquiry Price
Size
QTY
WZ8040
T67341214265-57-2
WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).
  • Inquiry Price
Size
QTY